Skip to content
Use your HSA or FSA funds

Condition report · Cardiovascular

Loeys-Dietz Syndrome

Whole genome sequencing evaluates TGFBR1, TGFBR2, SMAD3, TGFB2, and TGFB3 simultaneously, distinguishing Loeys-Dietz from Marfan syndrome and vascular Ehlers-Danlos, a distinction that directly determines aortic surgical intervention timing.

A condition report looks for rare variants known to cause the conditions it covers.

Included in Premium and Premium + AI

Premium adds $99 per kit for the first year.

Order with Premium

About this condition

A genetic connective tissue disorder characterized by arterial tortuosity, aneurysms, and dissections, particularly of the aorta, along with skeletal anomalies, craniofacial features, and skin findings.

Loeys-Dietz syndrome (LDS) is an autosomal dominant connective tissue disorder caused by pathogenic variants in genes encoding components of the transforming growth factor-beta (TGF-β) signaling pathway. LDS is genetically heterogeneous, with five recognized subtypes: LDS type 1 (TGFBR1), type 2 (TGFBR2), type 3 (SMAD3), type 4 (TGFB2), and type 5 (TGFB3). LDS was first described in 2005 and is characterized by a triad of features: arterial tortuosity and widespread aneurysm formation, hypertelorism (widely spaced eyes), and bifid or broad uvula or cleft palate. The cardiovascular features are the primary source of morbidity and mortality.

The critical clinical distinction between Loeys-Dietz syndrome and phenotypically similar conditions (particularly Marfan syndrome and vascular Ehlers-Danlos syndrome) lies in the aggressiveness of aortic disease. LDS patients experience aortic dissection at significantly smaller aortic root diameters than Marfan patients. While prophylactic aortic root replacement in Marfan syndrome is typically recommended at 5.0 cm, LDS guidelines recommend surgical intervention at 4.0-4.2 cm for aortic root diameter in LDS type 1 and 2. Additionally, LDS produces aneurysms throughout the arterial tree, not limited to the aortic root, requiring whole-body vascular imaging surveillance that is not standard in Marfan management.

Distinguishing LDS from Marfan syndrome requires molecular confirmation because the phenotypes overlap substantially: both can present with aortic root aneurysm, skeletal features (pectus deformity, scoliosis, joint hypermobility), and dural ectasia. A patient with LDS misclassified as Marfan syndrome would have their surgical intervention threshold set 1 cm above their actual safe limit, a difference that can be the boundary between prophylactic repair and emergency dissection. Genetic testing is therefore not ancillary to clinical diagnosis in this population; it is the primary determinant of surgical timing and surveillance strategy.

Five LDS subtypes have been defined based on the causative gene. TGFBR1 and TGFBR2 variants produce the most aggressive vascular phenotype; SMAD3, TGFB2, and TGFB3 variants tend toward milder disease with later onset but require equivalent vascular surveillance.

The 3 conditions we analyse

Loeys-Dietz Syndrome

Autosomal dominant

Loeys-Dietz syndrome is a rare genetic connective tissue disorder characterized by a broad spectrum of craniofacial, vascular and skeletal manifestations with five genetic subtypes described forming a clinical continuum.

Genes analysed

Also known as

aortic aneurysm syndrome due to TGF-beta receptors anomalies; aortic aneurysm syndrome, Loeys-Dietz type

Includes 6 related subtypes ↓
  • aneurysm-osteoarthritis syndrome
  • Loeys-Dietz syndrome 1
  • Loeys-Dietz syndrome 2
  • Loeys-Dietz syndrome 4
  • Loeys-Dietz syndrome 6
  • Rienhoff syndrome
MONDO:0018954Orphanet 60030MedGen 395827

Angiodysplasia

Acquired degenerative dilation or expansion (ectasia) of normal blood vessels, often associated with aging. They are isolated, tortuous, thin-walled vessels and sources of bleeding. They occur most often in mucosal capillaries of the gastrointestinal tract leading to gastrointestinal hemorrhage and anemia.

Also known as

angiodysplasia of stomach and duodenum with haemorrhage; angiodysplasia of stomach and duodenum with hemorrhage

Includes 2 related subtypes ↓
  • angiodysplasia of intestine
  • angiodysplasia of stomach
MONDO:0002322MedGen 88403

Why whole genome sequencing

Marfan panels test FBN1. LDS panels add TGFBR1/2. Neither approach captures all five LDS genes, the full connective tissue differential, and the intronic variants that explain genotype-negative familial aortic disease.

The differential between LDS, Marfan, and vascular EDS determines surgical management, not just diagnosis

Aortic root aneurysm in a young patient with connective tissue features triggers a differential that includes Marfan syndrome (FBN1), Loeys-Dietz syndrome (TGFBR1/TGFBR2/SMAD3/TGFB2/TGFB3), vascular Ehlers-Danlos syndrome (COL3A1), familial thoracic aortic aneurysm (ACTA2, MYH11), and others. Each diagnosis carries a different surgical threshold, different surveillance protocol, and different recommendations for activity restriction and pregnancy management. Sequential single-gene or limited-panel testing introduces delays: every month between clinical suspicion and molecular confirmation is a month during which the aortic root may be enlarging past the unrecognized true safe threshold. Whole genome sequencing evaluates all of these genes simultaneously in a single test.

De novo LDS variants are common: a negative family history does not exclude the diagnosis

Approximately 25-30% of LDS cases arise from de novo variants with no family history of aortic disease or connective tissue disorders. This means the first presentation of LDS in a family may be an acute aortic dissection in a young patient whose prior evaluation found 'no family history' and in whom a clinical-only assessment may not have triggered genetic testing. Having a complete genome result (including the TGF-β pathway genes) in the medical record before an acute vascular event provides the information needed for rapid clinical decision-making if an adverse vascular event occurs.

Other cardiovascular conditions

All conditions →

One test. A lifetime of answers.

One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. Physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.

From $449

Free shipping · Results in 6–8 weeks

Premium adds $99 per kit for the first year.

Order with Premium